AI Governance Meets FDA Validation

MedTech Leading Voice | Issue 174

📝 From the Editor

On a personal note, we crossed 9,000 subscribers on Friday morning, live during the call. Thank you all for subscribing!

This week's posts circle one thread: the regulatory scaffolding around AI and connected devices is being built out in real time, from EU AI Act classification to FDA validation of LLM-based devices. The frameworks that were theoretical a year ago now carry concrete compliance expectations.

— Sean Smith

🧠 Featured Post

FDA validation for LLM-based medical devices

David Pudwill laid out the validation problem that sits underneath every LLM-enabled submission: a model whose outputs shift with context is hard to pin to the fixed, reproducible evidence FDA review is built on. The challenge is not whether the technology works; it is how you demonstrate it works the same way every time.

For MedTech teams, this is the near-term gating issue on AI device strategy.

If your roadmap includes generative or LLM components, the validation approach needs to be scoped early, because it shapes your predicate logic, your test design, and how much of your submission the agency can actually accept.

View the post >>

📚 Featured Article

Set in Stone — Your Intended Use (Part 4): The Benefit-Risk Determination

Dr. Irene Thomas closes her four-part series on intended use with the benefit-risk determination under EU MDR.

Her core point: the benefit-risk profile is a clinical argument specific to your device, patient population, and the current state of the art, and Notified Bodies flag templated justifications as a common deficiency.

She walks through it with a total hip replacement example, from residual risks after ISO 14971 controls to the clinical endpoints that show whether benefits outweigh those risks, and notes that Article 61 requires the determination to stay favorable across the device's life as PMS and PMCF data evolve. Read the article >>

📌 This Week's Top Posts (In no special order)

• EU MDR Compliance clarified best practices for evaluating risk probability under ISO 14971.
• The key criteria for classifying AI-powered medical devices as high-risk under the EU AI Act, reviewed by Tibor Zechmeister.
• Leonard Eisner explained the structure behind the IEC 60601-1 4th Edition and its hazard-based development.
• EU MDR Article 16 requirements for relabelling and repackaging medical devices were summarized by Medtech Knowledge.
• Intrinsic Medical Group, LLC discussed updates to ISO 10993-7:2026 for EO-sterilized medical devices.
• Secure-by-default configuration principles for connected medical devices, overviewed by Jose Bohorquez.
• Mario Gabrielli Cossellu announced the publication of the 2025 EU Member States summaries on Notified Body monitoring activities.
• The hidden business costs of DIY medical device cybersecurity were emphasized by Garrett Sipple.
• Stefano Bolletta shared the new MDCG 2026-5 position paper on UDI assignment between manufacturers and distributors.
• Important considerations for selecting between the FDA's 510(k) and De Novo pathways were underscored by Mirna Hassoun.
• David Pudwill revealed the challenges surrounding FDA validation for LLM-based medical devices.

🎯 Featured Event

Designing Electronic Medical Devices That Actually Reach Production

Join Andre' DiMino, President and CEO of ADCO Manufacturing, for contract manufacturing and design, and what happens when a design that works on the bench meets a real production line. Friday, July 31, 2026 at 11:00 AM ET. Register Now >>

🗓️ Upcoming Events & Webinars

• Thursday, August 6, 2026 | 11:00 AM ET — Beyond the Protocol: A Realistic Resource and Planning Guide for Human Factors Validation Success, featuring Denise Forkey and Leya Bergquist (ClariMed) and Kira Favakeh (Medtronic). Register Now >>
• Wednesday, August 19, 2026 | 11:00 AM ET — When Enrollment Stops: Diagnosing a Study That's Already Gone Wrong, featuring Daniela Karrer (Donawa Lifescience). Register Now >>
• Wednesday, August 26, 2026 | 8:00 AM–5:00 PM ET — Project Medtech Startup Symposium, Quorum at the Science Center, Philadelphia, in collaboration with Penn Health-Tech. Use code MLV20 for 20% off. RSVP >>

💥 Weekly 510(k) Roundup

July 20, 2026 | From Marcus Engineering, LLC

40 clearances this week, including 11 first-time clearances (🚀). Featured clearances:

• Atlas Spine, Inc. — HiRISE™ Expandable Cervical Corpectomy Implant (Orthopedic): replaces an entire cervical vertebra when disease or injury requires its removal, and expands during the procedure so surgeons can fine-tune height and restore spinal stability per patient.
• 🚀 Cubresa, Inc. — BrainPET (Radiology): combines PET and MRI in a single scan and installs as an insert for existing MRI systems, making functional brain imaging more accessible for conditions like Alzheimer's, epilepsy, and brain tumors.
• 🚀 Virasoft Corporation — Virasight (Pathology): turns glass slides into high-resolution digital images so pathologists can review cases remotely, collaborate, and use AI-assisted tools in their workflow. Explore the update >>

📋 Regulatory Roundup

Monday, 20 July 2026 | By Martin King

This week's developments reinforce the move toward digital, data-driven, implementation-focused, and risk-based regulation across Europe, the United Kingdom, Switzerland, Australia, Asia, Brazil, and Egypt.

Organisations should prioritise structured regulatory data, digital regulatory platforms, UDI registration, quality management systems, clinical evidence, post-market surveillance, cybersecurity, AI governance, and privacy compliance.

Particular attention goes to clinical investigations, digital regulatory infrastructure, regulatory transparency, data governance, and continuous lifecycle management, as these are becoming baseline expectations across the global regulatory landscape.

Explore the update >>

🎤 In Case You Missed It

MDUFA VI: What Every MedTech Company Needs to Know Now

On Friday's In Focus, David Filmore broke down the MDUFA VI draft covering FY2028 through FY2032, which Congress must enact before October 1, 2027. Industry fees fund roughly half of CDRH's budget, so this agreement sets what companies pay and what they get for five years. The whole thing is still proposed, and the FDA comment window closes August 5. Watch the replay >>

🔥 Postscript

My big podcast debut with Etienne Nichols is live. Take a listen. Listen here >>

Sean 🐝